LEUVEN, Belgium and LUND, Sweden, February 23 /PRNewswire-FirstCall/ --
- Trial to Assess the Benefits of Partial Factor VIII Inhibition in Patients Undergoing Knee Replacement Surgery
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.
TB-402 is a recombinant human monoclonal antibody that targets Factor VIII, a key component of the coagulation cascade. TB-402 is a novel anticoagulant agent, which may deliver important clinical benefits due to it only partially inhibiting Factor VIII activity even when given in very high doses. This novel mode of action is expected to reduce the risk of undesirable bleeding events and the need for patient monitoring, the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent which means that patients are expected to receive just one single dose after surgery to prevent the development of DVT, as opposed to all current treatment options which require daily treatment for up to several weeks.
The Phase II trial is an active (enoxaparin)-controlled, dose-escalating,
multicenter, prospective, randomised, open label trial evaluating TB-402 for
the prophylaxis of DVT after knee surgery. The study will assess three
different doses of TB-402 given as a single intravenous bolus injection post
knee replacement surgery. The trial will enrol 300 patients across 36 centers
mainly in Central Europe. The primary endpoint is the safety and efficacy of
|SOURCE ThromboGenics NV|
Copyright©2009 PR Newswire.
All rights reserved